Fatimah S. Dawood

Fatimah S. Dawood

Auto-generated profile, based on publicly available information

Fatimah S. Dawood

2024 Influenza A(H5N1) Response, Centers for Disease Control and Prevention, Atlanta, Georgia

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2012 in The Lancet Infectious Diseases
Verified
Journal Article
Open access
FDFatimah S Dawood
Fatimah S Dawood
AIA Danielle Iuliano
A Danielle Iuliano
CRCarrie Reed
Carrie Reed
MMMartin I Meltzer
Martin I Meltzer
DSDavid K Shay
David K Shay
MWMarc-Alain Widdowson
Marc-Alain Widdowson
18,500 laboratory-confirmed deaths caused by the 2009 pandemic influenza A H1N1 were reported worldwide for the period April, 2009, to August, 2010. This number is likely to be only a fraction of the true number of the deaths associated with 2009 pandemic influenza A H1N1. We aimed to estimate the global number of deaths during the first 12 months of virus circulation in each country. We calculated crude respiratory mortality rates associated with the 2009 pandemic influenza A H1N1 strain by age (0-17 years, 18-64 years, and >64 years) using the cumulative (12 months) virus-associated symptomatic attack rates from 12 countries and symptomatic case fatality ratios (sCFR) from five high-income countries. To adjust crude mortality rates for differences between countries in risk of death from influenza, we developed a respiratory mortality multiplier equal to the ratio of the median lower respiratory tract infection mortality rate in each WHO region mortality stratum to the median in countries with very low mortality. We calculated cardiovascular disease mortality rates associated with 2009 pandemic influenza A H1N1 infection with the ratio of excess deaths from cardiovascular and respiratory diseases during the pandemic in five countries and multiplied these values by the crude respiratory disease mortality rate associated with the virus. Respiratory and cardiovascular mortality rates associated with 2009 pandemic influenza A H1N1 were multiplied by age to calculate the number of associated deaths. We estimate that globally there were 201,200 respiratory deaths (range 105,700-395,600) with an additional 83,300 cardiovascular deaths (46,000-179,900) associated with 2009 pandemic influenza A H1N1. 80% of the respiratory and cardiovascular deaths were in people younger than 65 years and 51% occurred in southeast Asia and Africa. Our estimate of respiratory and cardiovascular mortality associated with the 2009 pandemic influenza A H1N1 was 15 times higher than reported laboratory-confirmed deaths. Although no estimates of sCFRs were available from Africa and southeast Asia, a disproportionate number of estimated pandemic deaths might have occurred in these regions. Therefore, efforts to prevent influenza need to effectively target these regions in future pandemics. None.

28 August 2013 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
FDFatimah S. Dawood
Fatimah S. Dawood
SCSandra S. Chaves
Sandra S. Chaves
APAlejandro Pérez
Alejandro Pérez
ARArthur Reingold
Arthur Reingold
JMJames Meek
James Meek
FNFor The Emerging Infections Program Network
For The Emerging Infections Program Network
Background. Data on the range and severity of influenza-associated complications among children are limited. We describe the frequency and severity of complications in hospitalized children aged <18 years with seasonal influenza (during 2003–2009) and 2009 pandemic influenza A(H1N1) (during 2009–2010). Methods. Population-based surveillance for laboratory-confirmed influenza hospitalizations was conducted among 5.3 million children in 10 states. Complications were identified by International Classification of Diseases, Ninth Revision (ICD-9) codes in medical records. Results. During 2003–2010, 7293 children hospitalized with influenza were identified, of whom 6769 (93%) had complete ICD-9 code data. Among the 6769 children, the median length of hospitalization was 3 days (interquartile range, 2–4 days), 975 (14%) required intensive care, 359 (5%) had respiratory failure, and 40 (1%) died. The most common complications were pneumonia (in 28% of children), asthma exacerbations (in 22% [793/3616] aged ≥2 years), and dehydration (in 21%). Lung abscess/empyema, tracheitis, encephalopathy, bacteremia/sepsis, acute renal failure, and myocarditis were rare (each ≤2% of children) but associated with a median hospitalization duration of ≥6 days, and 48%–70% of children required intensive care. Bacterial cultures with positive results were identified in 2% of children (107/6769); Staphylococcus aureus and Streptococcus pneumoniae were most commonly identified. Conclusions. Complications contribute substantially to the disease burden among children hospitalized with influenza, through intensive care requirements and prolonged hospitalization, highlighting the importance of primary prevention with influenza vaccination.

8 October 2021 in JAMA Pediatrics
Verified
Journal Article
Open access
PDF file
FDFatimah S. Dawood
Fatimah S. Dawood
CPChristina A. Porucznik
Christina A. Porucznik
VVVic Veguilla
Vic Veguilla
JSJoseph B. Stanford
Joseph B. Stanford
JDJazmin Duque
Jazmin Duque
MSMelissa S. Stockwell
Melissa S. Stockwell
Differences have been observed in SARS-CoV-2 infection frequency and clinical presentation among children compared with adults since the earliest months of the COVID-19 pandemic. In early case series of SARS-CoV-2 infections,1-4 children accounted for a minority of cases, which raised questions about whether children were tested for SARS-CoV-2 less frequently than adults because of differences in clinical presentation, care seeking, or access to testing; had fewer opportunities for exposure because of prevention measures; or in fact were less susceptible to infection because of differences in baseline immune status. Multiple studies have now suggested that children are more likely than adults to have asymptomatic or atypical SARS-CoV-2 infections that may not meet COVID-19 case definitions.5-7 At the same time, seroprevalence,8-10 household,11-13 outbreak,14,15 and surveillance studies have now clearly established that children are susceptible to SARS-CoV-2. However, findings remain mixed with respect to the relative risk of infection among children compared with adults.16 Most studies that have drawn inferences about risk among children vs adults lacked systematic, longitudinal testing for both asymptomatic and symptomatic infections or relied on serologic markers of infection that may not always be present or sustained after asymptomatic infection.17,18 Both limitations might lead to underdetection of SARS-CoV-2 infection cases among children and the false conclusion that risk of infection is lower among children than adults.

21 February 2020 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Closed access
FDFatimah S Dawood
Fatimah S Dawood
JCJessie R Chung
Jessie R Chung
SKSara S Kim
Sara S Kim
RZRichard K Zimmerman
Richard K Zimmerman
MNMary Patricia Nowalk
Mary Patricia Nowalk
BFBrendan Flannery
Brendan Flannery
CDC preliminary vaccine effectiveness estimates show 2019–20 influenza vaccines providing substantial protective benefit, particularly among children, who have been hard hit by influenza this season. Influenza vaccines are reducing the risk for having to go to the doctor with influenza illness by 45% overall and by 55% in children.

1 November 2010 in The Journal of Pediatrics
Verified
Journal Article
Closed access
FDFatimah S. Dawood
Fatimah S. Dawood
AFAnthony Fiore
Anthony Fiore
LKLaurie Kamimoto
Laurie Kamimoto
ABAnna Bramley
Anna Bramley
ARArthur Reingold
Arthur Reingold
LFLyn Finelli
Lyn Finelli

1 January 2021 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
FDFatimah S Dawood
Fatimah S Dawood
WKWanitchaya Kittikraisak
Wanitchaya Kittikraisak
APArchana Patel
Archana Patel
DHDanielle Rentz Hunt
Danielle Rentz Hunt
PSPiyarat Suntarattiwong
Piyarat Suntarattiwong
YTYeny Tinoco
Yeny Tinoco